Takashi Nojiri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Takashi Nojiri has a total of 486 co-authors. Here are the top co-authors by number of shared publications:
Meinoshin Okumura
Department of General Thoracic Surgery, Osaka University Graduate School of Medicine, Suita‑City, Japan
24 shared publicationsHiroshi Hosoda
Department of Regenerative Medicine and Tissue Engineering, National Cerebral and Cardiovascular Center, Suita‑City, Japan
15 shared publicationsHajime Maeda
Department of General Thoracic Surgery, National Hospital Organization Toneyama Hospital, Toyonaka, Japan
14 shared publicationsMikiya Miyazato
Department of Biochemistry, National Cerebral and Cardiovascular Center Research Institute, Suita‑City, Japan
14 shared publicationsYukiyasu Takeuchi
Department of General Thoracic Surgery, National Hospital Organization Toneyama Hospital, Toyonaka, Japan
14 shared publicationsKenji Kangawa
Department of Biochemistry, National Cerebral and Cardiovascular Center Research Institute, Suita‑City, Japan
13 shared publications
Latest Publications
- 21 August 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (761) , eadn0904
Modified C-type natriuretic peptide normalizes tumor vasculature, reinvigorates antitumor immunity, and improves solid tumor therapies
Deficit of oxygen and nutrients in the tumor microenvironment (TME) triggers abnormal angiogenesis that produces dysfunctional and leaky blood vessels, which fail to adequately perfuse tumor tissues. Resulting hypoxia, exacerbation of metabolic disturbances, and generation of an immunosuppressive TME undermine the efficacy of anticancer therapies. Use of carefully scheduled angiogenesis inhibitors has been suggested to overcome these problems and normalize the TME. Here, we propose an alternative agonist-based normalization approach using a derivative of the C-type natriuretic peptide (dCNP). Multiple gene expression signatures in tumor tissues were affected in mice treated with dCNP. In several mouse orthotopic and subcutaneous solid tumor models including colon and pancreatic adenocarcinomas, this well-tolerated agent stimulated formation of highly functional tumor blood vessels to reduce hypoxia. Administration of dCNP also inhibited stromagenesis and remodeling of the extracellular matrix and decreased tumor interstitial fluid pressure. In addition, treatment with dCNP reinvigorated the antitumor immune responses. Administration of dCNP decelerated growth of primary mouse tumors and suppressed their metastases. Moreover, inclusion of dCNP into the chemo-, radio-, or immune-therapeutic regimens increased their efficacy against solid tumors in immunocompetent mice. These results demonstrate the proof of principle for using vasculature normalizing agonists to improve therapies against solid tumors and characterize dCNP as the first in class among such agents.
- 21 August 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (761) , eadn0904
Modified C-type natriuretic peptide normalizes tumor vasculature, reinvigorates antitumor immunity, and improves solid tumor therapies
Deficit of oxygen and nutrients in the tumor microenvironment (TME) triggers abnormal angiogenesis that produces dysfunctional and leaky blood vessels, which fail to adequately perfuse tumor tissues. Resulting hypoxia, exacerbation of metabolic disturbances, and generation of an immunosuppressive TME undermine the efficacy of anticancer therapies. Use of carefully scheduled angiogenesis inhibitors has been suggested to overcome these problems and normalize the TME. Here, we propose an alternative agonist-based normalization approach using a derivative of the C-type natriuretic peptide (dCNP). Multiple gene expression signatures in tumor tissues were affected in mice treated with dCNP. In several mouse orthotopic and subcutaneous solid tumor models including colon and pancreatic adenocarcinomas, this well-tolerated agent stimulated formation of highly functional tumor blood vessels to reduce hypoxia. Administration of dCNP also inhibited stromagenesis and remodeling of the extracellular matrix and decreased tumor interstitial fluid pressure. In addition, treatment with dCNP reinvigorated the antitumor immune responses. Administration of dCNP decelerated growth of primary mouse tumors and suppressed their metastases. Moreover, inclusion of dCNP into the chemo-, radio-, or immune-therapeutic regimens increased their efficacy against solid tumors in immunocompetent mice. These results demonstrate the proof of principle for using vasculature normalizing agonists to improve therapies against solid tumors and characterize dCNP as the first in class among such agents.
- RetractionOpen Access
- 21 December 2023
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 93 (3) , 271
Retraction Note: Atrial natriuretic peptide protects against cisplatin‑induced granulocytopenia
- 21 December 2023
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 93 (3) , 271
RetractionOpen AccessRetraction Note: Atrial natriuretic peptide protects against cisplatin‑induced granulocytopenia
- RetractionOpen Access
- 24 March 2022
- Published by Impact Journals, LLC in Oncotarget
- Vol. 13 (1) , 551-552
Retraction: Transcriptome analysis reveals a role for the endothelial ANP-GC-A signaling in interfering with pre-metastatic niche formation by solid cancers
Https://doi.org/10.18632/oncotarget.28223 Takashi Nojiri, Miki Arai, Yutaka Suzuki, Motofumi Kumazoe, Takeshi Tokudome, Koichi Miura, Jun Hino, Hiroshi Hosoda, Mikiya Miyazato, Meinoshin Okumura,...
- 24 March 2022
- Published by Impact Journals, LLC in Oncotarget
- Vol. 13 (1) , 551-552
RetractionOpen AccessRetraction: Transcriptome analysis reveals a role for the endothelial ANP-GC-A signaling in interfering with pre-metastatic niche formation by solid cancers
Https://doi.org/10.18632/oncotarget.28223 Takashi Nojiri, Miki Arai, Yutaka Suzuki, Motofumi Kumazoe, Takeshi Tokudome, Koichi Miura, Jun Hino, Hiroshi Hosoda, Mikiya Miyazato, Meinoshin Okumura,...
- Open Access
- 1 March 2022
- Published by International College of Surgeons in International Surgery
- Vol. 106 (2) , 67-74
Preoperative Oral-Bowel Preparation Using Sodium Picosulfate and Magnesium Citrate Combination Powder for Left-Sided Colorectal Cancer: A Prospective Study
Objective: This study aimed to determine if induction of sodium picosulfate and magnesium citrate (SPMC) preparation leads to adequate surgery for left-sided colorectal cancer (CRC).Summary of Background Data: Adequate bowel cleansing is vital for safe and accurate colorectal surgery. Ingestion of laxatives for bowel cleansing may be associated with a broad spectrum of adverse effects during surgical intervention.Methods: A single-center prospective study was conducted with hospitalized patients scheduled operation for left-sided CRC. All enrolled patients were instructed to consume normal diet until before preparation. Twenty-seven patients underwent preoperative SPMC preparation.Results: The primary endpoint of this study was the 30-day postoperative morbidity rate, which was 23%, and no postoperative complication was higher than Clavien-Dindo grade 3. The primary anastomosis rate was 100%, and there was no anastomotic leakage. The colonic cleansing grades were 1 or 2 according to the bowel preparation scale for surgical assessment in 89% of the patients. The acceptability of the cleansing procedure by the patients assessed by a questionnaire was 85%, and the acceptability of the SPMC preparation by the medical staff was 93%. The surgical procedures included 18 laparoscopies, 6 robotic surgeries, and 3 laparotomies. The median operation time was 165 minutes, and the median blood loss was <50 cc. The median sodium serum concentration was significantly decreased after surgery.Conclusion: Ingestion of an SPMC preparation as a cleansing procedure was judged to be adequate for curative surgery in patients with left-sided colorectal cancer.
- 1 March 2022
- Published by International College of Surgeons in International Surgery
- Vol. 106 (2) , 67-74
Open AccessPreoperative Oral-Bowel Preparation Using Sodium Picosulfate and Magnesium Citrate Combination Powder for Left-Sided Colorectal Cancer: A Prospective Study
Objective: This study aimed to determine if induction of sodium picosulfate and magnesium citrate (SPMC) preparation leads to adequate surgery for left-sided colorectal cancer (CRC).Summary of Background Data: Adequate bowel cleansing is vital for safe and accurate colorectal surgery. Ingestion of laxatives for bowel cleansing may be associated with a broad spectrum of adverse effects during surgical intervention.Methods: A single-center prospective study was conducted with hospitalized patients scheduled operation for left-sided CRC. All enrolled patients were instructed to consume normal diet until before preparation. Twenty-seven patients underwent preoperative SPMC preparation.Results: The primary endpoint of this study was the 30-day postoperative morbidity rate, which was 23%, and no postoperative complication was higher than Clavien-Dindo grade 3. The primary anastomosis rate was 100%, and there was no anastomotic leakage. The colonic cleansing grades were 1 or 2 according to the bowel preparation scale for surgical assessment in 89% of the patients. The acceptability of the cleansing procedure by the patients assessed by a questionnaire was 85%, and the acceptability of the SPMC preparation by the medical staff was 93%. The surgical procedures included 18 laparoscopies, 6 robotic surgeries, and 3 laparotomies. The median operation time was 165 minutes, and the median blood loss was <50 cc. The median sodium serum concentration was significantly decreased after surgery.Conclusion: Ingestion of an SPMC preparation as a cleansing procedure was judged to be adequate for curative surgery in patients with left-sided colorectal cancer.
- Retraction
- 15 November 2021
- Published by Springer Nature in Surgery Today
- Vol. 52 (1) , 165
Retraction Note to: Inhaled tiotropium to prevent postoperative cardiopulmonary complications in patients with newly diagnosed chronic obstructive pulmonary disease requiring lung cancer surgery
- 15 November 2021
- Published by Springer Nature in Surgery Today
- Vol. 52 (1) , 165
RetractionRetraction Note to: Inhaled tiotropium to prevent postoperative cardiopulmonary complications in patients with newly diagnosed chronic obstructive pulmonary disease requiring lung cancer surgery
- RetractionOpen Access
- 1 June 2021
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 59 (6) , 1352
Retraction to ‘Low-dose human atrial natriuretic peptide for the prevention of postoperative cardiopulmonary complications in chronic obstructive pulmonary disease patients undergoing lung cancer surgery’
Following an investigation of the National University Corporation Osaka University, the authors requested this article to be retracted.
- 1 June 2021
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 59 (6) , 1352
RetractionOpen AccessRetraction to ‘Low-dose human atrial natriuretic peptide for the prevention of postoperative cardiopulmonary complications in chronic obstructive pulmonary disease patients undergoing lung cancer surgery’
Following an investigation of the National University Corporation Osaka University, the authors requested this article to be retracted.
- 1 April 2018
- Published by Elsevier in Journal of Surgical Research
- Vol. 224, 50-57
Chemotherapy can promote liver metastasis by enhancing metastatic niche formation in mice
- 1 April 2018
- Published by Elsevier in Journal of Surgical Research
- Vol. 224, 50-57
Chemotherapy can promote liver metastasis by enhancing metastatic niche formation in mice
- Open Access
- 10 October 2017
- Published by Springer Nature in BMC Pharmacology and Toxicology
- Vol. 18 (S1) , 1-35
Abstracts from the 8th International Conference on cGMP Generators, Effectors and Therapeutic Implications
- 10 October 2017
- Published by Springer Nature in BMC Pharmacology and Toxicology
- Vol. 18 (S1) , 1-35
Open AccessAbstracts from the 8th International Conference on cGMP Generators, Effectors and Therapeutic Implications